Top investors in AI for physicians and health systems are the venture firms and corporate funds backing software that clinicians and hospitals buy directly: documentation, clinical decision support, billing and patient operations.
TL;DR
Thirteen AI companies selling to physicians and health systems raised about $1.02 billion in disclosed 2026 rounds tracked by AI Funding, and Heidi Health's $340 million accounted for a third of it. Y Combinator backed six of the thirteen companies, Insight Partners led three rounds, and Andreessen Horowitz led two. Provider-facing AI drew roughly 7% of the $14.3 billion raised in US-dollar AI healthcare rounds in 2026; drug discovery took 58%.
Key Takeaways
- $1.02B across 13 rounds: Heidi Health, Laza Medical, Candid Health, Pearl Health, Bunkerhill Health, Charta Health, Healthleap, Prosper AI, Vera Health, TytoCare, Triomics, Parallel and Assured Health raised a combined $1,022.5M in disclosed 2026 rounds.
- Y Combinator is the most frequent name: YC appears on the cap tables of 6 of the 13 companies (Candid Health, Bunkerhill Health, Prosper AI, Vera Health, Triomics and Parallel), more than any other investor.
- Insight Partners is the most frequent lead: it led Charta Health's $55M Series B, Assured Health's $19M Series A and TytoCare's $25M-plus growth round.
- Andreessen Horowitz led two rounds: Prosper AI's $30M Series A and the $50M equity portion of Pearl Health's $110M raise.
- Clinical AI took the largest share: five clinical-intelligence companies (Heidi Health, Bunkerhill Health, Healthleap, Vera Health and Triomics) raised $483.5M, 47% of the cohort.
- Strategic money is part of the picture: GE HealthCare led Laza Medical's Series B of up to $160M, and Optum Ventures and Qualcomm Ventures appear in Bunkerhill Health's and TytoCare's rounds.
What counts as AI for physicians and health systems?
This analysis covers one buyer: the clinician or the provider organisation. A company qualifies if its product is bought by hospitals, health systems, physician groups or clinics to run care or the business of care. That rules out three large categories that often get grouped with "healthcare AI":
- Drug discovery and biology models (Isomorphic Labs, Chai Discovery, Enveda), whose customers are pharmaceutical pipelines, not providers.
- Consumer health and insurance (Neko Health, Alan, Function Health), which sell to patients or members.
- Life-sciences data vendors such as xCures, whose named customers in its $46M Series B were Exact Sciences, Caris Life Sciences and Novocure rather than hospitals.
The cohort is also limited to rounds whose investors we could confirm in the announcement or in reporting on it. Two large provider-facing raises in our dataset, Assort Health's $120M Series C and Suki's $90M Series E, are left out of the investor counts because our records do not yet name the investors from a primary source.
Which AI companies for physicians and health systems raised the most in 2026?
| Company | Date | Round | Amount | Lead investor(s) | Other named investors |
|---|---|---|---|---|---|
| Heidi Health | Sep 2026 | Series C + growth | $340M | Blackbird (Series C); General Catalyst ($240M growth) | Phoenix Court, Point72 Private Investments, Headline |
| Laza Medical | Nov 2026 | Series B | Up to $160M | GE HealthCare | Unorthodox Ventures, PA MedTech, AMED |
| Candid Health | Jul 2026 | Series D | $120M | Sixth Street Growth | Oak HC/FT, 8VC, Y Combinator |
| Pearl Health | Jul 2026 | Equity + credit | $110M | Andreessen Horowitz (equity); Trinity Capital (debt) | Viking Global Investors, AlleyCorp, Ulysses Capital |
| Bunkerhill Health | Jul 2026 | Series B | $55M | Not named | Sequoia Capital, Felicis, Optum Ventures, Y Combinator, Khosla Ventures |
| Charta Health | Nov 2026 | Series B | $55M | Insight Partners | Madrona, Bain Capital Ventures, South Park Commons, QuantumLight |
| Healthleap | Oct 2026 | Seed + Series A | $38M | Hummingbird Ventures (A); Sequoia Capital and First Round Capital (seed) | — |
| Prosper AI | Jun 2026 | Series A | $30M | Andreessen Horowitz | Base10 Partners, Emergence Capital, Y Combinator, Company Ventures |
| Vera Health | Oct 2026 | Series A | $28.5M | Threshold Ventures | Mantis VC, SV Angel, Y Combinator, Gradient |
| TytoCare | Jul 2026 | Growth | $25M+ | Insight Partners | HOOP, OliveTree, OrbiMed, Qumra Capital, Qualcomm Ventures |
| Triomics | May 2026 | Series B | $22M | Battery Ventures | Nexus Venture Partners, Lightspeed, Y Combinator |
| Parallel | Mar 2026 | Series A | $20M | Index Ventures | Frst, Y Combinator, Hexa |
| Assured Health | Jul 2026 | Series A | $19M | Insight Partners | First Round Capital, Kindred Ventures |
Two notes on reading the table. Heidi Health's $340M combines a $100M Series C with $240M of growth investment from General Catalyst, so one company and two separate checks make up a third of the cohort. Pearl Health's $110M is $50M of equity plus a $60M credit facility; only the equity portion is venture ownership. Without Heidi, the other twelve companies raised $682.5M, a median round of $34M.
Who are the top investors in AI for physicians and health systems?
Counting every confirmed appearance, lead or follow-on, across the 13 rounds:
| Investor | Companies backed in cohort | Rounds led | Portfolio companies |
|---|---|---|---|
| Y Combinator | 6 | 0 | Candid Health, Bunkerhill Health, Prosper AI, Vera Health, Triomics, Parallel |
| Insight Partners | 3 | 3 | Charta Health, Assured Health, TytoCare |
| Andreessen Horowitz | 2 | 2 | Prosper AI, Pearl Health |
| Sequoia Capital | 2 | 1 (seed co-lead) | Bunkerhill Health, Healthleap |
| First Round Capital | 2 | 1 (seed co-lead) | Healthleap, Assured Health |
| General Catalyst | 1 | 1 (growth) | Heidi Health |
| GE HealthCare | 1 | 1 | Laza Medical |
| Blackbird | 1 | 1 | Heidi Health |
| Sixth Street Growth | 1 | 1 | Candid Health |
Y Combinator is the clearest pattern. It led none of these rounds, but its alumni are now raising Series A through Series D. YC was an existing backer that came back in Candid Health's Series D, Bunkerhill Health's Series B and Triomics' Series B, and Vera Health's release names YC as an existing investor that added to its position. For a founder building for clinicians, the accelerator is the most common first check in this group.
Insight Partners is the most active lead, and its three deals share a theme: the administrative plumbing of provider organisations. Charta Health sells billing accuracy (revenue up 10x in 12 months, total funding $85M); Assured Health automates credentialing and getting providers in-network (over 100 provider customers, including Houston Methodist); TytoCare sells remote-examination tools to care organisations.
Andreessen Horowitz backed two companies that sit between providers and payment: Prosper AI's voice agents for patient access (serving over 150,000 healthcare providers, according to the company) and Pearl Health's value-based-care platform for primary care (more than 10,000 providers and over 250,000 Medicare beneficiaries).
Sequoia Capital and First Round Capital both appear at the earliest stage. They co-led Healthleap's $8M seed before Hummingbird Ventures led its $30M Series A, and Sequoia is a continuing backer of Bunkerhill Health.
Which product categories are investors funding?
| Category | Companies | Combined raise | Share of cohort |
|---|---|---|---|
| Clinical intelligence (documentation, decision support, patient flagging) | Heidi Health, Bunkerhill Health, Healthleap, Vera Health, Triomics | $483.5M | 47% |
| Care delivery and devices | Laza Medical, Pearl Health, TytoCare | $295M | 29% |
| Revenue cycle and administration | Candid Health, Charta Health, Prosper AI, Parallel, Assured Health | $244M | 24% |
The clinical intelligence group is where the large checks went. Heidi Health reports an enterprise activation rate of around 62% across health systems, counts Beth Israel Lahey Health as a customer and is sole supplier for NHS England Midlands. Vera Health says more than 800,000 clinicians in 190 countries use its clinical-knowledge tool. Healthleap flags hospitalised patients who need a closer look and is deployed in more than 50 hospitals.
The revenue cycle group raised less per company but carries some of the strongest growth figures in the cohort. Candid Health reported 190% annual recurring revenue growth and net revenue retention close to 200%, and Fortune reported that its round tripled its 2025 valuation (no dollar figure was disclosed). Charta Health grew revenue 10x in a year. Parallel, a Paris company, says its agents are live in dozens of public and private hospitals.
Which health systems are the reference customers?
Investors in this space buy evidence that a health system will deploy, not just pilot. The announcements behind these rounds name the following provider customers:
| Health system or provider | Vendors in this cohort naming it |
|---|---|
| Intermountain Health | Bunkerhill Health, Healthleap |
| Houston Methodist | Healthleap, Assured Health |
| Cleveland Clinic | Bunkerhill Health |
| University of Texas Medical Branch | Bunkerhill Health |
| Penn Medicine, Cedars-Sinai, Emory Healthcare | Healthleap |
| Memorial Sloan Kettering, Yale Cancer Center | Triomics |
| Beth Israel Lahey Health, NHS England Midlands | Heidi Health |
Intermountain and Houston Methodist each appear for two different vendors. For investors, a short list of large academic and integrated systems acts as the early-adopter market, and a logo there often appears in the funding announcement itself. Bunkerhill reports that UTMB runs more than 20 agents on its platform, and that one nephrology triage agent cut average specialist wait times by more than half (a company-reported figure, not independently audited).
How does provider-facing AI compare with the rest of healthcare AI funding?
Across the 109 US-dollar rounds in our AI Healthcare sector dated 2026, companies raised $14.3 billion. Eight rounds at seven drug-discovery and biology-model companies, led by Isomorphic Labs' $5.0B Series C and $2.1B Series B, account for $8.36B, or 58% of the total. The 13 provider-facing rounds above account for about 7%.
That gap explains the investor list. Drug-discovery rounds of a billion dollars or more go to model-heavy companies backed by large growth and sovereign funds. Provider AI is still an early- and mid-stage market where accelerators, enterprise-software specialists like Insight Partners and generalist firms like a16z and Sequoia write $20M to $55M checks, with a few growth rounds above $100M. Strategic investors with distribution into hospitals (GE HealthCare, Optum Ventures, Qualcomm Ventures) take part where a product touches a device or an existing provider channel.
What should founders and health-system buyers take from this?
- The first check is usually an accelerator or a seed specialist. YC, First Round and Sequoia's seed appearances in this cohort are earlier than the Series A leads that follow.
- Series A and B leads specialise by workflow. Insight Partners concentrates on administration and billing, Battery Ventures led oncology-specific Triomics, and Index Ventures led Parallel's European hospital-administration play.
- Growth rounds follow proven deployment. Heidi Health's and Candid Health's large rounds came with named enterprise customers and disclosed growth rates, not just pilots.
- Health systems are concentrated as early customers. If the same few academic systems keep appearing, a vendor's reference list overlaps heavily with its competitors'.
FAQ
Who are the top investors in AI for physicians and health systems in 2026?
By number of companies backed in our 13-round cohort, Y Combinator leads with six portfolio companies. Insight Partners led the most rounds (Charta Health, Assured Health and TytoCare), and Andreessen Horowitz led two (Prosper AI and Pearl Health's equity). Sequoia Capital and First Round Capital each appear twice.
Which AI company for health systems raised the most money in 2026?
Heidi Health, which builds AI agents for clinicians and health systems, raised $340M in September 2026: a $100M Series C led by Blackbird plus $240M in growth investment from General Catalyst.
How much did AI startups for physicians and hospitals raise in 2026?
The 13 provider-facing rounds confirmed in this analysis total about $1.02 billion. That is roughly 7% of the $14.3 billion raised across US-dollar AI healthcare rounds in AI Funding's 2026 data; drug discovery took 58%.
Do strategic healthcare companies invest in clinical AI startups?
Yes. GE HealthCare led Laza Medical's Series B of up to $160M for intelligent cath-lab imaging, Optum Ventures is a continuing backer of Bunkerhill Health, and Qualcomm Ventures and OrbiMed joined TytoCare's growth round.
Sources
- SiliconANGLE: Heidi Health nabs $340M to deepen adoption of AI agents within health systems
- Fortune: Candid Health raises $120 million to take on medical billing
- PR Newswire: Pearl Health raises $110 million
- TechCrunch: Healthleap raises $38M for AI that flags hospital patients
- AI News: Bunkerhill raises $55M to scale agentic AI for health systems
- PR Newswire: Charta Health raises $55 million Series B
- PR Newswire: Vera Health raises $32 million
- Tech Funding News: Prosper AI raises $30M Series A
- TechCrunch: Triomics nabs $22M to bring oncology-specific AI to cancer centers
- MedCity News: Assured Health raises $19M for healthcare credentialing
- Tech Funding News: Parallel raises $20M from Index Ventures
- PR Newswire: TytoCare closes $25M growth round
- PR Newswire: Laza Medical raises up to $160 million in Series B financing led by GE HealthCare
- Tech Funding News: Isomorphic Labs lands $5B Series C
- Crunchbase News: xCures lands Series B for medical records AI
For the full investor ranking, see AI Funding's top AI healthcare investors and the AI healthcare sector page, which update as new rounds are tracked.
Top comments (0)